PhaseBio Pharmaceuticals Inc

-0.05 (-2.51%)
Earnings Announcements

Phasebio Reports Third-Quarter 2021 Financial Results And Recent Business Highlights

Published: 11/10/2021 21:09 GMT
PhaseBio Pharmaceuticals Inc (PHAS) - Phasebio Reports Third-quarter 2021 Financial Results and Recent Business Highlights.
Cash and Cash Equivalents at September 30, 2021 Were $56.4 Million.
Qtrly Loss per Share $0.66.
Q3 Earnings per Share View $-0.61 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $3.28 Million
Adjusted EPS is expected to be -$0.56

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.57

More details on our Analysts Page.